Natural compounds proposed for the management of non-alcoholic fatty liver disease

IF 4.8 3区化学 Q1 CHEMISTRY, MEDICINAL Natural Products and Bioprospecting Pub Date : 2024-04-01 DOI:10.1007/s13659-024-00445-z

Théodora Merenda, Florian Juszczak, Elisabeth Ferier, Pierre Duez, Stéphanie Patris, Anne-Émilie Declèves, Amandine Nachtergael

{"title":"Natural compounds proposed for the management of non-alcoholic fatty liver disease","authors":"Théodora Merenda, Florian Juszczak, Elisabeth Ferier, Pierre Duez, Stéphanie Patris, Anne-Émilie Declèves, Amandine Nachtergael","doi":"10.1007/s13659-024-00445-z","DOIUrl":null,"url":null,"abstract":"<div><p>Although non-alcoholic fatty liver disease (NAFLD) presents as an intricate condition characterized by a growing prevalence, the often-recommended lifestyle interventions mostly lack high-level evidence of efficacy and there are currently no effective drugs proposed for this indication. The present review delves into NAFLD pathology, its diverse underlying physiopathological mechanisms and the available in vitro<i>, </i>in vivo, and clinical evidence regarding the use of natural compounds for its management, through three pivotal targets (oxidative stress, cellular inflammation, and insulin resistance). The promising perspectives that natural compounds offer for NAFLD management underscore the need for additional clinical and lifestyle intervention trials. Encouraging further research will contribute to establishing more robust evidence and practical recommendations tailored to patients with varying NAFLD grades.</p><h3>Graphical Abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":718,"journal":{"name":"Natural Products and Bioprospecting","volume":null,"pages":null},"PeriodicalIF":4.8000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10982245/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Natural Products and Bioprospecting","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s13659-024-00445-z","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Although non-alcoholic fatty liver disease (NAFLD) presents as an intricate condition characterized by a growing prevalence, the often-recommended lifestyle interventions mostly lack high-level evidence of efficacy and there are currently no effective drugs proposed for this indication. The present review delves into NAFLD pathology, its diverse underlying physiopathological mechanisms and the available in vitro, in vivo, and clinical evidence regarding the use of natural compounds for its management, through three pivotal targets (oxidative stress, cellular inflammation, and insulin resistance). The promising perspectives that natural compounds offer for NAFLD management underscore the need for additional clinical and lifestyle intervention trials. Encouraging further research will contribute to establishing more robust evidence and practical recommendations tailored to patients with varying NAFLD grades.

Graphical Abstract

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

建议用于治疗非酒精性脂肪肝的天然化合物。

尽管非酒精性脂肪肝（NAFLD）是一种复杂的疾病，其特点是发病率越来越高，但人们经常推荐的生活方式干预措施大多缺乏高水平的疗效证据，目前也没有针对这一适应症的有效药物。本综述通过三个关键靶点（氧化应激、细胞炎症和胰岛素抵抗），深入探讨了非酒精性脂肪肝的病理、其各种潜在的生理病理机制，以及有关使用天然化合物治疗非酒精性脂肪肝的现有体外、体内和临床证据。天然化合物为非酒精性脂肪肝的治疗提供了广阔的前景，强调了进行更多临床和生活方式干预试验的必要性。鼓励开展进一步的研究，将有助于为非酒精性脂肪肝不同等级的患者提供更有力的证据和实用的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊